Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers.

Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, Emu B, Norris PJ, Busch MP, Martin JN, Brooks C, McCune JM, Deeks SG.

PLoS One. 2011 Jan 31;6(1):e15924. doi: 10.1371/journal.pone.0015924.

2.

Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG.

J Infect Dis. 2008 Jan 1;197(1):126-33. doi: 10.1086/524143.

3.

HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers.

Hunt PW, Hatano H, Sinclair E, Lee TH, Busch MP, Martin JN, McCune JM, Deeks SG.

Clin Infect Dis. 2011 Mar 1;52(5):681-7. doi: 10.1093/cid/ciq202. Epub 2011 Jan 18.

4.

HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses.

Owen RE, Heitman JW, Hirschkorn DF, Lanteri MC, Biswas HH, Martin JN, Krone MR, Deeks SG, Norris PJ; NIAID Center for HIV/AIDS Vaccine Immunology.

AIDS. 2010 May 15;24(8):1095-105. doi: 10.1097/QAD.0b013e3283377a1e.

5.
6.

Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal.

Legrand FA, Nixon DF, Loo CP, Ono E, Chapman JM, Miyamoto M, Diaz RS, Santos AM, Succi RC, Abadi J, Rosenberg MG, de Moraes-Pinto MI, Kallas EG.

PLoS One. 2006 Dec 20;1:e102.

7.

Severe immune dysregulation affects CD4⁺CD25(hi)FoxP3⁺ regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy.

Méndez-Lagares G, Pozo-Balado MM, Genebat M, García Pergañeda A, Leal M, Pacheco YM.

J Infect Dis. 2012 May 15;205(10):1501-9. doi: 10.1093/infdis/jis230. Epub 2012 Mar 28. Erratum in: J Infect Dis. 2012 Dec 15;206(12):1951. del Mar del Pozo Balado, María [corrected to Pozo-Balado, María M]; Genebat González, Miguel [corrected to Genebat, Miguel]; García Pergañeda Sánchez, Antonio [corrected to García-Pergañeda, Antonio]; Leal Noval, Manuel [corrected to Leal, Manuel]; Pacheco López, Yolanda María [corrected to Pacheco, Yolanda María].

PMID:
22457273
8.

HLA-DR expression on regulatory T cells is closely associated with the global immune activation in HIV-1 infected subjects naïve to antiretroviral therapy.

Xiao J, Qian KL, Cao QH, Qiu CL, Qiu C, Xue YL, Zhang XY, Zhong P, Xu JQ, Li MY, Wang Y.

Chin Med J (Engl). 2011 Aug;124(15):2340-6.

PMID:
21933566
9.

Particular activation phenotype of T cells expressing HLA-DR but not CD38 in GALT from HIV-controllers is associated with immune regulation and delayed progression to AIDS.

Gonzalez SM, Taborda NA, Correa LA, Castro GA, Hernandez JC, Montoya CJ, Rugeles MT.

Immunol Res. 2016 Jun;64(3):765-74. doi: 10.1007/s12026-015-8775-5.

PMID:
26724942
10.

Incomplete normalization of regulatory t-cell frequency in the gut mucosa of Colombian HIV-infected patients receiving long-term antiretroviral treatment.

Rueda CM, Velilla PA, Chougnet CA, Rugeles MT.

PLoS One. 2013 Aug 15;8(8):e71062. doi: 10.1371/journal.pone.0071062. eCollection 2013.

11.

Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy.

Weiss L, Piketty C, Assoumou L, Didier C, Caccavelli L, Donkova-Petrini V, Levy Y, Girard PM, Burgard M, Viard JP, Rouzioux C, Costagliola D; ANRS 116 SALTO study group.

PLoS One. 2010 Jul 21;5(7):e11659. doi: 10.1371/journal.pone.0011659.

12.

Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers.

Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, Somsouk M, Deeks SG, Shacklett BL.

J Virol. 2011 Nov;85(21):11422-34. doi: 10.1128/JVI.05608-11. Epub 2011 Aug 31.

13.

Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation.

Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, Somsouk M, Deeks SG, Shacklett BL.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):172-7. doi: 10.1089/AID.2012.0268. Epub 2012 Oct 16.

14.

HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.

Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, Deeks SG.

J Virol. 2008 Jun;82(11):5398-407. doi: 10.1128/JVI.02176-07. Epub 2008 Mar 19.

15.

A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers.

Tomescu C, Liu Q, Ross BN, Yin X, Lynn K, Mounzer KC, Kostman JR, Montaner LJ.

PLoS One. 2014 Jul 31;9(7):e103209. doi: 10.1371/journal.pone.0103209. eCollection 2014.

16.

Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1.

Bello G, Velasco-de-Castro CA, Bongertz V, Rodrigues CA, Giacoia-Gripp CB, Pilotto JH, Grinsztejn B, Veloso VG, Morgado MG.

J Med Virol. 2009 Oct;81(10):1681-90. doi: 10.1002/jmv.21565.

PMID:
19697415
17.

HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype.

Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barré-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A; Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group.

Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81. Epub 2007 Apr 11.

18.

Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study.

Potter SJ, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M, Colle JH, Urrutia A, Scott-Algara D, Boufassa F, Delfraissy JF, Thèze J, Venet A, Chakrabarti LA.

J Virol. 2007 Dec;81(24):13904-15. Epub 2007 Oct 10.

19.

HIV controllers are distinguished by chemokine expression profile and HIV-specific T-cell proliferative potential.

Card CM, Keynan Y, Lajoie J, Bell CP, Dawood M, Becker M, Kasper K, Fowke KR.

J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):427-37. doi: 10.1097/QAI.0b013e3182454fcd.

PMID:
22240463
20.

Composition and function of T cell subpopulations are slow to change despite effective antiretroviral treatment of HIV disease.

Emu B, Moretto WJ, Hoh R, Krone M, Martin JN, Nixon DF, Deeks SG, McCune JM.

PLoS One. 2014 Jan 21;9(1):e85613. doi: 10.1371/journal.pone.0085613. eCollection 2014.

Supplemental Content

Support Center